Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats.
Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats.
复制标题
DOI：
10.1038/bjc.1979.203
复制
发表时间：
1979-09
影响因子：
8.8
通讯作者：
Qureshi, S A
中科院分区：
文献类型：
--
作者：
Reddy, J K;Qureshi, S A
以15只雄性F344大鼠为研究对象，以0.5% （v/w）的浓度连续饲喂28个月的降血脂药物乙基- α -对氯苯氧异丁酸乙酯（乙基- α -对氯苯氧异丁酸乙酯）。在24至28个月间死亡的大鼠中有10/11（91%）发生肝细胞癌。其他肿瘤包括胰腺癌（2只大鼠）、小肠平滑肌瘤（1只大鼠）和大皮肤纤维肉瘤（1只大鼠）。Clofibrate是第三种被证实在大鼠中具有肝癌致癌性的低血脂过氧化物酶体增殖剂。这些研究表明，能够产生持续肝肿大和过氧化物酶体增殖作用的降血脂药物也可诱导肝肿瘤。
Ethyl-alpha-p-chlorophenoxyisobutyrate), a hypolipidaemic drug which induces hepatomegaly and proliferation of peroxisomes in liver cells of rats and mice, was fed to 15 male F344 rats at a dietary concentration of 0.5% (v/w) for up to 28 months. Hepatocellular carcinomas developed in 10/11 (91%) rats killed between 24 and 28 months. Other tumours included carcinoma of the pancreas (2 rats), leiomyoma of the small intestine (1 rat) and a large dermatofibrosarcoma (1 rat). Clofibrate is the third hypolipidaemic peroxisome proliferator demonstrated to be hepatocarcinogenic in rats. These studies suggest that hypolipidaemic agents which are capable of producing a sustained hepatomegalic and peroxisome-proliferative effect also induce liver tumours.